Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy
Phase of Trial: Phase IV
Latest Information Update: 12 Oct 2016
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BLAST
- 07 Jun 2017 Biomarkers information updated
- 03 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 03 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.